The majority of early stage breast cancer patients are diagnosed with an estrogen receptor positive (ER+) and HER2 receptor negative (HER2−) disease, associated with favorable outcomes, and patients benefit from endocrine therapy. This evidence concerns the gene ERBB2 and breast carcinoma.